Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome

Patricio Ray, David Acheson, Ramona Chitrakar, Avital Cnaan, Kathleen Gibbs, Gladys H. Hirschman, Erica Christen, Howard Trachtman, Julie Ingelfinger, Josephine Briggs, John Kusek, Daniel Cattran, Mitchell B. Cohen, Katherine Freeman, Thomas Greene, Solomon Moshe, Seth Schulman, James Springate, Frederick Kaskel, Dilys Whyte & 26 others Robert Weiss, Charles McKay, Lewis Reisman, Eduardo Perelstein, Manju Chandra, Jose Salcedo, Lynne Weiss, William Varade, Douglas Ford, James Chan, Irene Restaino, Shashi Nagaraj, Victoria Norwood, John Foreman, Michael Moritz, John Mahan, Marva Moxey-Mims, Barry Warshaw, Verna Yiu, Andrew Brem, Sharon Bartosh, Sharon Andreoli, Lawrence Milner, Jens Goebel, Dianne Muchant, Coral Hanevold

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Diarrhea-associated hemolytic uremic syndrome (D+HUS) is characterized by endothelial injury and activation of inflammatory cytokines. Basic fibroblast growth factor (bFGF) is an angiogenic peptide released in response to vascular damage. The plasma concentrations and urinary excretion of bFGF during the course of D+HUS were determined, in comparison with the levels of various inflammatory cytokines, and changes were correlated with clinical and laboratory features of the disease. Serial plasma and urine samples were collected from 31 children with D+HUS, during the acute (days 1 to 7 of hospitalization) and recovery (through day 60 after discharge from the hospital) phases of the disease. The patients were enrolled in the multicenter trial of SYNSORB Pk (SYNSORB Biotech, Calgary, Alberta, Canada) treatment for D+HUS. bFGF, interleukin-1α (IL-1α), IL-8, and tumor necrosis factor-α levels were determined with enzyme-linked immunosorbent assays. bFGF was detected in urine and plasma samples more frequently than were IL-1α, IL-8, and tumor necrosis factor-α. There was an acute increase in urinary bFGF excretion, which returned to normal during convalescence. Urinary excretion of bFGF during the acute phase was higher among patients who required dialysis, compared with those who did not (48.9 ± 15.0 and 28.9 ± 9.0 pg/ml, respectively; P <0.05). Plasma bFGF concentrations were persistently elevated throughout the period of hospitalization and the follow-up period among patients with D+HUS. Urinary excretion and plasma levels of bFGF were comparable for the SYNSORB Pk-treated (n = 19) and placebo-treated (n = 12) groups. Measurements of urinary and plasma concentrations of bFGF among patients with D+HUS may be useful indices for assessment of the severity of acute renal disease and the timing and adequacy of the systemic angiogenic process during early convalescence.

Original languageEnglish (US)
Pages (from-to)699-707
Number of pages9
JournalJournal of the American Society of Nephrology
Volume13
Issue number3
StatePublished - 2002
Externally publishedYes

Fingerprint

Hemolytic-Uremic Syndrome
Fibroblast Growth Factor 2
Diarrhea
Interleukin-8
Interleukin-1
Hospitalization
Tumor Necrosis Factor-alpha
Angiogenic Proteins
Urine
Cytokines
Fibroblast Growth Factor 1
Alberta
Acute Disease
Multicenter Studies
Canada
Blood Vessels
Dialysis
Enzyme-Linked Immunosorbent Assay
Placebos
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Ray, P., Acheson, D., Chitrakar, R., Cnaan, A., Gibbs, K., Hirschman, G. H., ... Hanevold, C. (2002). Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. Journal of the American Society of Nephrology, 13(3), 699-707.

Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. / Ray, Patricio; Acheson, David; Chitrakar, Ramona; Cnaan, Avital; Gibbs, Kathleen; Hirschman, Gladys H.; Christen, Erica; Trachtman, Howard; Ingelfinger, Julie; Briggs, Josephine; Kusek, John; Cattran, Daniel; Cohen, Mitchell B.; Freeman, Katherine; Greene, Thomas; Moshe, Solomon; Schulman, Seth; Springate, James; Kaskel, Frederick; Whyte, Dilys; Weiss, Robert; McKay, Charles; Reisman, Lewis; Perelstein, Eduardo; Chandra, Manju; Salcedo, Jose; Weiss, Lynne; Varade, William; Ford, Douglas; Chan, James; Restaino, Irene; Nagaraj, Shashi; Norwood, Victoria; Foreman, John; Moritz, Michael; Mahan, John; Moxey-Mims, Marva; Warshaw, Barry; Yiu, Verna; Brem, Andrew; Bartosh, Sharon; Andreoli, Sharon; Milner, Lawrence; Goebel, Jens; Muchant, Dianne; Hanevold, Coral.

In: Journal of the American Society of Nephrology, Vol. 13, No. 3, 2002, p. 699-707.

Research output: Contribution to journalArticle

Ray, P, Acheson, D, Chitrakar, R, Cnaan, A, Gibbs, K, Hirschman, GH, Christen, E, Trachtman, H, Ingelfinger, J, Briggs, J, Kusek, J, Cattran, D, Cohen, MB, Freeman, K, Greene, T, Moshe, S, Schulman, S, Springate, J, Kaskel, F, Whyte, D, Weiss, R, McKay, C, Reisman, L, Perelstein, E, Chandra, M, Salcedo, J, Weiss, L, Varade, W, Ford, D, Chan, J, Restaino, I, Nagaraj, S, Norwood, V, Foreman, J, Moritz, M, Mahan, J, Moxey-Mims, M, Warshaw, B, Yiu, V, Brem, A, Bartosh, S, Andreoli, S, Milner, L, Goebel, J, Muchant, D & Hanevold, C 2002, 'Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome', Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 699-707.
Ray, Patricio ; Acheson, David ; Chitrakar, Ramona ; Cnaan, Avital ; Gibbs, Kathleen ; Hirschman, Gladys H. ; Christen, Erica ; Trachtman, Howard ; Ingelfinger, Julie ; Briggs, Josephine ; Kusek, John ; Cattran, Daniel ; Cohen, Mitchell B. ; Freeman, Katherine ; Greene, Thomas ; Moshe, Solomon ; Schulman, Seth ; Springate, James ; Kaskel, Frederick ; Whyte, Dilys ; Weiss, Robert ; McKay, Charles ; Reisman, Lewis ; Perelstein, Eduardo ; Chandra, Manju ; Salcedo, Jose ; Weiss, Lynne ; Varade, William ; Ford, Douglas ; Chan, James ; Restaino, Irene ; Nagaraj, Shashi ; Norwood, Victoria ; Foreman, John ; Moritz, Michael ; Mahan, John ; Moxey-Mims, Marva ; Warshaw, Barry ; Yiu, Verna ; Brem, Andrew ; Bartosh, Sharon ; Andreoli, Sharon ; Milner, Lawrence ; Goebel, Jens ; Muchant, Dianne ; Hanevold, Coral. / Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. In: Journal of the American Society of Nephrology. 2002 ; Vol. 13, No. 3. pp. 699-707.
@article{7f34ccb3feab4cbd821caade5254b2a0,
title = "Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome",
abstract = "Diarrhea-associated hemolytic uremic syndrome (D+HUS) is characterized by endothelial injury and activation of inflammatory cytokines. Basic fibroblast growth factor (bFGF) is an angiogenic peptide released in response to vascular damage. The plasma concentrations and urinary excretion of bFGF during the course of D+HUS were determined, in comparison with the levels of various inflammatory cytokines, and changes were correlated with clinical and laboratory features of the disease. Serial plasma and urine samples were collected from 31 children with D+HUS, during the acute (days 1 to 7 of hospitalization) and recovery (through day 60 after discharge from the hospital) phases of the disease. The patients were enrolled in the multicenter trial of SYNSORB Pk (SYNSORB Biotech, Calgary, Alberta, Canada) treatment for D+HUS. bFGF, interleukin-1α (IL-1α), IL-8, and tumor necrosis factor-α levels were determined with enzyme-linked immunosorbent assays. bFGF was detected in urine and plasma samples more frequently than were IL-1α, IL-8, and tumor necrosis factor-α. There was an acute increase in urinary bFGF excretion, which returned to normal during convalescence. Urinary excretion of bFGF during the acute phase was higher among patients who required dialysis, compared with those who did not (48.9 ± 15.0 and 28.9 ± 9.0 pg/ml, respectively; P <0.05). Plasma bFGF concentrations were persistently elevated throughout the period of hospitalization and the follow-up period among patients with D+HUS. Urinary excretion and plasma levels of bFGF were comparable for the SYNSORB Pk-treated (n = 19) and placebo-treated (n = 12) groups. Measurements of urinary and plasma concentrations of bFGF among patients with D+HUS may be useful indices for assessment of the severity of acute renal disease and the timing and adequacy of the systemic angiogenic process during early convalescence.",
author = "Patricio Ray and David Acheson and Ramona Chitrakar and Avital Cnaan and Kathleen Gibbs and Hirschman, {Gladys H.} and Erica Christen and Howard Trachtman and Julie Ingelfinger and Josephine Briggs and John Kusek and Daniel Cattran and Cohen, {Mitchell B.} and Katherine Freeman and Thomas Greene and Solomon Moshe and Seth Schulman and James Springate and Frederick Kaskel and Dilys Whyte and Robert Weiss and Charles McKay and Lewis Reisman and Eduardo Perelstein and Manju Chandra and Jose Salcedo and Lynne Weiss and William Varade and Douglas Ford and James Chan and Irene Restaino and Shashi Nagaraj and Victoria Norwood and John Foreman and Michael Moritz and John Mahan and Marva Moxey-Mims and Barry Warshaw and Verna Yiu and Andrew Brem and Sharon Bartosh and Sharon Andreoli and Lawrence Milner and Jens Goebel and Dianne Muchant and Coral Hanevold",
year = "2002",
language = "English (US)",
volume = "13",
pages = "699--707",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome

AU - Ray, Patricio

AU - Acheson, David

AU - Chitrakar, Ramona

AU - Cnaan, Avital

AU - Gibbs, Kathleen

AU - Hirschman, Gladys H.

AU - Christen, Erica

AU - Trachtman, Howard

AU - Ingelfinger, Julie

AU - Briggs, Josephine

AU - Kusek, John

AU - Cattran, Daniel

AU - Cohen, Mitchell B.

AU - Freeman, Katherine

AU - Greene, Thomas

AU - Moshe, Solomon

AU - Schulman, Seth

AU - Springate, James

AU - Kaskel, Frederick

AU - Whyte, Dilys

AU - Weiss, Robert

AU - McKay, Charles

AU - Reisman, Lewis

AU - Perelstein, Eduardo

AU - Chandra, Manju

AU - Salcedo, Jose

AU - Weiss, Lynne

AU - Varade, William

AU - Ford, Douglas

AU - Chan, James

AU - Restaino, Irene

AU - Nagaraj, Shashi

AU - Norwood, Victoria

AU - Foreman, John

AU - Moritz, Michael

AU - Mahan, John

AU - Moxey-Mims, Marva

AU - Warshaw, Barry

AU - Yiu, Verna

AU - Brem, Andrew

AU - Bartosh, Sharon

AU - Andreoli, Sharon

AU - Milner, Lawrence

AU - Goebel, Jens

AU - Muchant, Dianne

AU - Hanevold, Coral

PY - 2002

Y1 - 2002

N2 - Diarrhea-associated hemolytic uremic syndrome (D+HUS) is characterized by endothelial injury and activation of inflammatory cytokines. Basic fibroblast growth factor (bFGF) is an angiogenic peptide released in response to vascular damage. The plasma concentrations and urinary excretion of bFGF during the course of D+HUS were determined, in comparison with the levels of various inflammatory cytokines, and changes were correlated with clinical and laboratory features of the disease. Serial plasma and urine samples were collected from 31 children with D+HUS, during the acute (days 1 to 7 of hospitalization) and recovery (through day 60 after discharge from the hospital) phases of the disease. The patients were enrolled in the multicenter trial of SYNSORB Pk (SYNSORB Biotech, Calgary, Alberta, Canada) treatment for D+HUS. bFGF, interleukin-1α (IL-1α), IL-8, and tumor necrosis factor-α levels were determined with enzyme-linked immunosorbent assays. bFGF was detected in urine and plasma samples more frequently than were IL-1α, IL-8, and tumor necrosis factor-α. There was an acute increase in urinary bFGF excretion, which returned to normal during convalescence. Urinary excretion of bFGF during the acute phase was higher among patients who required dialysis, compared with those who did not (48.9 ± 15.0 and 28.9 ± 9.0 pg/ml, respectively; P <0.05). Plasma bFGF concentrations were persistently elevated throughout the period of hospitalization and the follow-up period among patients with D+HUS. Urinary excretion and plasma levels of bFGF were comparable for the SYNSORB Pk-treated (n = 19) and placebo-treated (n = 12) groups. Measurements of urinary and plasma concentrations of bFGF among patients with D+HUS may be useful indices for assessment of the severity of acute renal disease and the timing and adequacy of the systemic angiogenic process during early convalescence.

AB - Diarrhea-associated hemolytic uremic syndrome (D+HUS) is characterized by endothelial injury and activation of inflammatory cytokines. Basic fibroblast growth factor (bFGF) is an angiogenic peptide released in response to vascular damage. The plasma concentrations and urinary excretion of bFGF during the course of D+HUS were determined, in comparison with the levels of various inflammatory cytokines, and changes were correlated with clinical and laboratory features of the disease. Serial plasma and urine samples were collected from 31 children with D+HUS, during the acute (days 1 to 7 of hospitalization) and recovery (through day 60 after discharge from the hospital) phases of the disease. The patients were enrolled in the multicenter trial of SYNSORB Pk (SYNSORB Biotech, Calgary, Alberta, Canada) treatment for D+HUS. bFGF, interleukin-1α (IL-1α), IL-8, and tumor necrosis factor-α levels were determined with enzyme-linked immunosorbent assays. bFGF was detected in urine and plasma samples more frequently than were IL-1α, IL-8, and tumor necrosis factor-α. There was an acute increase in urinary bFGF excretion, which returned to normal during convalescence. Urinary excretion of bFGF during the acute phase was higher among patients who required dialysis, compared with those who did not (48.9 ± 15.0 and 28.9 ± 9.0 pg/ml, respectively; P <0.05). Plasma bFGF concentrations were persistently elevated throughout the period of hospitalization and the follow-up period among patients with D+HUS. Urinary excretion and plasma levels of bFGF were comparable for the SYNSORB Pk-treated (n = 19) and placebo-treated (n = 12) groups. Measurements of urinary and plasma concentrations of bFGF among patients with D+HUS may be useful indices for assessment of the severity of acute renal disease and the timing and adequacy of the systemic angiogenic process during early convalescence.

UR - http://www.scopus.com/inward/record.url?scp=0036185829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036185829&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 699

EP - 707

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 3

ER -